# NanO2 in Large VessEL Occlusion Stroke (NOVEL)

Study · id `cardio:ct-nct06821347` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06821347](<https://clinicaltrials.gov/study/NCT06821347>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06821347

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 172 participants.

## Technical summary

Registry record NCT06821347. Randomized; double masking; primary purpose treatment. Start 2025-05-01 (anticipated); primary completion 2026-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 172 participants (planned count; ClinicalTrials.gov record NCT06821347, source copy `cardio:ctgov-nct06821347-2025-04-04`, retrieved 2026-10-26)
- Planned start: 2025-05-01 (anticipated) (ClinicalTrials.gov record NCT06821347, source copy `cardio:ctgov-nct06821347-2025-04-04`, retrieved 2026-10-26)
- Primary completion: 2026-07-31 (anticipated) (ClinicalTrials.gov record NCT06821347, source copy `cardio:ctgov-nct06821347-2025-04-04`, retrieved 2026-10-26)
- Completion: 2026-07-31 (anticipated) (ClinicalTrials.gov record NCT06821347, source copy `cardio:ctgov-nct06821347-2025-04-04`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT06821347, source copy `cardio:ctgov-nct06821347-2025-04-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06821347-2025-04-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: NanO2 in Large VessEL Occlusion Stroke (NOVEL)
- Acronym: NOVEL
- Condition: Stroke Acute
- Intervention (Drug): NanO2TM
- Intervention (Other): Sodium Chloride 0.9% Intravenous
- Lead sponsor: NHS Greater Glasgow and Clyde
- Lead sponsor class: OTHER
- Collaborator: University of Glasgow
- Collaborator class: OTHER
- Collaborator: NuvOx LLC
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: NHS Greater Glasgow and Clyde (`cardio:org-nhs-greater-glasgow-and-clyde`)
- Registry lists this organization as a collaborator: University of Glasgow (`cardio:org-university-of-glasgow`)

## Provenance

Content hash: 3707c23a7437b1264d35fbdfbf2c7962369866b70f21534ba63cbcf80227c421
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
